Table 1.

Effects of rapamycin treatment on mTOR signaling pathway in the cerebellum of WT and AS mice

	WT/vehicle	WT/rapamycin	AS/vehicle	AS/rapamycin
mTOR/β-actin
P2	100.0 ± 2.6	117.6 ± 8.4	122.2 ± 11.44	105.0 ± 11.7
S2	100.0 ± 3.7	66.0 ± 3.0**	85.0 ± 4.6	59.2 ± 3.9##
S6K1/β-actin
P2	100.0 ± 11.4	104.4 ± 4.7	91.0 ± 11.3	93.0 ± 6.6
S2	100.0 ± 6.3	119.6 ± 4.8	105.6 ± 3.7	116.3 ± 6.2
AKT/β-actin
P2	100.0 ± 0.8	115.6 ± 6.4	107.2 ± 2.2	107.3 ± 3.4
S2	100.0 ± 3.6	93.2 ± 4.0	97.9 ± 11.7	82.5 ± 3.9
rictor/β-actin
P2	100.0 ± 2.7	62.4 ± 6.2**	97.6 ± 1.8	72.2 ± 8.1#
S2	100.0 ± 7.2	95.3 ± 6.7	108.4 ± 1.7	75.8 ± 5.4##
p-AKT 308/AKT
P2	100.0 ± 2.6	118.0 ± 11.0	78.7 ± 7.0*	150.5 ± 1.6###
S2	100.0 ± 4.6	104.5 ± 7.0	53.8 ± 8.9*	84.4 ± 4.9#
p-IRS1/IRS1
P2	100.0 ± 14.3	138.3 ± 7.7	288.0 ± 50.7*	246.3 ± 62.1
S2	100.0 ± 21.1	44.5 ± 6.	84.7 ± 27.2	77.8 ± 19.4
p-ERK/ERK
P2	100.0 ± 2.8	149.8 ± 14.6*	110.1 ± 11.0	131.9 ± 11.9
S2	100.0 ± 10.6	155.5 ± 11.5*	165.9 ± 10.5**	228.3 ± 31.5

All quantitative data of Western blot analyses are presented as means ± SEMs from 3–5 mice;

*p < 0.05,

**p < 0.01 compared with vehicle-treated WT mice;

^#p < 0.05,

^##p < 0.01,

^###p < 0.001 compared with vehicle-treated AS mice, two-way ANOVA with Newman–Keuls post hoc test.